These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 8650868)

  • 41. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia.
    Roehrborn CG; Boyle P; Gould AL; Waldstreicher J
    Urology; 1999 Mar; 53(3):581-9. PubMed ID: 10096388
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diagnostic value of percent free prostate-specific antigen: retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0 ng/mL.
    Törnblom M; Norming U; Adolfsson J; Becker C; Abrahamsson PA; Lilja H; Gustafsson O
    Urology; 1999 May; 53(5):945-50. PubMed ID: 10223488
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Diagnostic yield of repeated transrectal ultrasound-guided biopsies stratified by specific histopathologic diagnoses and prostate specific antigen levels.
    Roehrborn CG; Pickens GJ; Sanders JS
    Urology; 1996 Mar; 47(3):347-52. PubMed ID: 8633400
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Stratification of prostate-specific antigen level and results of transrectal ultrasonography and digital rectal examination as predictors of positive prostate biopsy.
    Clark TW; Goldenberg L; Cooperberg PL; Wong AD; Singer J
    Can Assoc Radiol J; 1997 Aug; 48(4):252-8. PubMed ID: 9282157
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The value of percent free prostate specific antigen, prostate specific antigen density of the whole prostate and of the transition zone in Turkish men.
    Akduman B; Alkibay T; Tuncel A; Bozkirli I
    Can J Urol; 2000 Oct; 7(5):1104-9. PubMed ID: 11114873
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical outcome of transrectal ultrasound-guided prostate biopsy, targeting eight cores, for detecting prostate cancer in Japanese men.
    Ishimura T; Sakai I; Hara I; Eto H; Miyake H
    Int J Clin Oncol; 2004 Feb; 9(1):47-50. PubMed ID: 15162826
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Systematic biopsies accurately predict extracapsular extension of prostate cancer and persistent/recurrent detectable PSA after radical prostatectomy.
    Ravery V; Boccon-Gibod LA; Dauge-Geffroy MC; Billebaud T; Delmas V; Meulemans A; Toublanc M; Boccon-Gibod L
    Urology; 1994 Sep; 44(3):371-6. PubMed ID: 7521093
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Predictive value of the international prostate symptom score for positive prostate needle biopsy in the low-intermediate prostate-specific antigen range.
    Kefi A; Irer B; Ozdemir I; Tuna B; Goktay Y; Yorukoğlu K; Esen A
    Urol Int; 2005; 75(3):222-6. PubMed ID: 16215309
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Detection of prostate cancer and changes in prostate-specific antigen (PSA) six months after surgery for benign prostatic hyperplasia in patients with elevated PSA.
    Ozden C; Inal G; Adsan O; Yazici S; Ozturk B; Cetinkaya M
    Urol Int; 2003; 71(2):150-3. PubMed ID: 12890951
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The risks of prostate cancer detection by transrectal ultrasound guide biopsy in Thai men with abnormal prostatic-specific antigen or abnormal digital rectal examination.
    Leewansangtong S; Tantiwong A; Ratanarapee S; Nualyong C; Soontrapa S
    J Med Assoc Thai; 2000 Dec; 83(12):1519-24. PubMed ID: 11253893
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Detection rates of nonpalpable prostate cancer in Korean men with prostate-specific antigen levels between 2.5 and 4.0 ng/mL.
    Kim HS; Jeon SS; Choi JD; Kim W; Han DH; Jeong BC; Seo SI; Lee KS; Lee SW; Lee HM; Choi HY
    Urology; 2010 Oct; 76(4):919-22. PubMed ID: 20303152
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Incidence of prostatic cancer in symptomatic patients with non-suspicious rectal palpation and PSA levels greater than 10 ng/ml].
    Herranz Amo F; Verdú Tartajo F; Díez Cordero JM; Bueno Chomón G; Leal Hernández F; Bielsa Carrillo A; García Burgos J
    Actas Urol Esp; 1999 Apr; 23(4):316-22. PubMed ID: 10394651
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Diagnostic significance of digital rectal examination and transrectal ultrasonography in men with prostate-specific antigen levels of 4 NG/ML or less.
    Yamamoto T; Ito K; Ohi M; Kubota Y; Suzuki K; Fukabori Y; Kurokawa K; Yamanaka H
    Urology; 2001 Dec; 58(6):994-8. PubMed ID: 11744475
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Detection of prostate cancer in males with prostatism.
    Lepor H; Owens RS; Rogenes V; Kuhn E
    Prostate; 1994 Sep; 25(3):132-40. PubMed ID: 7520577
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves.
    Catalona WJ; Richie JP; deKernion JB; Ahmann FR; Ratliff TL; Dalkin BL; Kavoussi LR; MacFarlane MT; Southwick PC
    J Urol; 1994 Dec; 152(6 Pt 1):2031-6. PubMed ID: 7525994
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of patients with diseases of the prostate using prostate-specific antigen density.
    Wolff JM; Boeckmann W; Effert PJ; Handt S; Jakse G
    Br J Urol; 1995 Jul; 76(1):41-6. PubMed ID: 7544203
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The use of prostate specific antigen density to predict clinically significant prostate cancer.
    Yusim I; Krenawi M; Mazor E; Novack V; Mabjeesh NJ
    Sci Rep; 2020 Nov; 10(1):20015. PubMed ID: 33203873
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Diagnostic values of digital rectal examination, prostate specific antigen and trans-rectal ultrasound in men with prostatism.
    Manyahi JP; Musau P; Mteta AK
    East Afr Med J; 2009 Sep; 86(9):450-3. PubMed ID: 21644416
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Contribution of PSA and its density in the diagnosis and tracking of the prostate cancer].
    Yousra S; Rafik E; Manel M; Kacem M
    Ann Biol Clin (Paris); 2010; 68(5):585-93. PubMed ID: 20870581
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Incidental carcinoma of the prostate.
    van Andel G; Vleeming R; Kurth K; de Reijke TM
    Semin Surg Oncol; 1995; 11(1):36-45. PubMed ID: 7538693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.